FDA Advisory Committee Meeting On Obesity Drugs Urged
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Obesity Working Group suggests the agency hold an advisory committee meeting to discuss existing drug therapies for obesity
You may also be interested in...
Obesity Drug Development On Tap For Advisory Committee Meeting In Fall
FDA's Metabolic & Endocrine and Food Advisory Committees are slated to discuss the agency's obesity treatment initiatives at a joint September meeting, Acting Commissioner Lester Crawford said at the World Obesity Congress in Washington, D.C. July 12
Obesity Drug Development On Tap For Advisory Committee Meeting In Fall
FDA's Metabolic & Endocrine and Food Advisory Committees are slated to discuss the agency's obesity treatment initiatives at a joint September meeting, Acting Commissioner Lester Crawford said at the World Obesity Congress in Washington, D.C. July 12
FDA/NIH Diabetes Public Meeting
FDA and the National Institutes of Health will hold a joint public meeting May 13 and 14 to discuss the treatment of type 1 and type 2 diabetes mellitus